• Overview
  • Eligibility
  • More info
  • Locations

A Pilot Study Evaluating Megestrol Acetate Modulation in Advanced Breast Cancer With Positive Hormonal Receptor (NCT03024580)

Cancer Research UK Cambridge Institute
This pilot trial evaluates in vivo megestrol acetate (MA) modulation of steroidal receptors in advanced breast cancer.
  • Drug: Megestrol Acetate 160Mg Tablet
    Megestrol acetate 160 mg PO daily
    • MA
  • Drug: Anastrozole 1Mg Tablet
    Anastrozole 1 mg PO daily OR
    • Anastrozole
  • Drug: Letrozole 2.5Mg Tablet
    Letrozole 2.5 mg PO daily OR
    • Letrozole
  • Drug: Exemestane 25 MG
    Exemestane 25 mg PO daily
    • Exemestane
  • Drug: Tamoxifen 20Mg Tablet
    Tamoxifen 20 mg PO daily
    • Tamoxifen
  • Drug: Fulvestrant 50Mg Solution for Injection
    Fulvestrant 500 mg IM d1, d14, d28 and q28 days
    • Fulvestrant
Ages eligible for Study
Genders eligible for Study
Accepts Healthy Volunteers
Inclusion Criteria:
  • Metastatic breast cancer with ER and/or PR positive (primary tumor)
  • Metastatic site amenable to biopsy
Exclusion Criteria:
  • Platelet count below 100,000 / mm3
  • Renal or hepatic impairment
  • Coagulation disorder
Progesterone receptor (PR) expression has been considered a biomarker of oestrogen receptor-α (ERα) activity. This longstanding relationship has been recently challenged and instead of being merely an ERα-induced gene target, PR may be a critical determinant of ERα activity. The functional significance of this steroid receptor crosstalk is regulation of a gene expression program associated with low tumorigenicity; hence, better disease outcome. Genomic alterations in the PR genomic locus seem to be a relatively common mechanism for reduction of PR expression, which may consequently lead to altered ERα chromatin binding and target gene expression patterns that increase breast tumorigenicity and confers a poor clinical outcome. This ERα-PR crosstalk may be directly influenced by many variables, including the relative receptor levels and the hormonal milieu.

ER-positive advanced breast cancer is a heterogeneous group of diseases with considerable variability in outcome to a range of treatments. Prior response predicts the likelihood of subsequent benefit from another endocrine agent and this should be taken into account in the treatment decision process when assessing whether to prescribe a subsequent endocrine therapy. Despite the enormous progress made regarding the elucidation of breast cancer subgroups and their molecular drivers, most information comes from primary tumors. MA lacks cross-resistance and is active after acquired resistance to potent AI. This pilot trial evaluates in vivo MA modulation of steroidal receptors in advanced breast cancer.

1 locations

Brazil (1)
  • Hospital do Cancer III
    Not specified
    Rio de Janeiro, Brazil, 20560120
not yet recruiting
28 February, 2017
15 January, 2017
A girl giving information about available additional trials.

FindMeCure helps you find, understand and join clinical trials from all over the world.

There are more clinical trials for your condition!